Meppadi

Chronic kidney disease (CKD) affects over 800 million people worldwide and is expected to become the 5th leading cause of death by 2040. CKD progresses to kidney failure, increases risks of early death and heart disease, and reduces quality of life. Current treatments do not fully prevent kidney failure, so this trial aims to find the best treatment or combination of treatments to slow CKD progression. CAPTIVATE is a Phase III, international, multi-center, adaptive platform trial designed to answer multiple treatment questions efficiently within a single research framework. Participants receive study treatments, such as Finerenone or placebo tablets taken orally once daily, for two years. They may be involved in more than one treatment at the same time or at different times. Follow-up visits occur around 1 month, 3 months, 6 months, 12 months, 18 months, and 2 years after starting treatment, with a final visit one month after treatment ends. The trial is ongoing and flexible, allowing new treatments to be added or removed based on results. During the study, participants have blood and urine tests, safety assessments, and treatment adherence monitoring. Health information is collected at study visits and every five years to evaluate long-term outcomes. The main measurement is the change in kidney function (eGFR slope) from the start of treatment to week 108. The study continues recruiting participants for many years to improve CKD treatment options.